Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Webinar presentation - Regimen I expands to 240 participants 28 May 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to provide the following presentation which will be used in the Company’s webinar scheduled for 4:00pm AEST (2:00pm AWST) on Thursday, 28 May 2026. The webinar will provide additional details regarding the recently announced expansion of Regimen I in the HEALEY ALS Platform Trial from 160 to 240 participants, including the strategic rationale for the expanded cohort, ongoing recruitment momentum across the HEALEY network, accelerated timelines to topline results, no change in financial implications and the broader strategic significance for the NUZ-001 program and Neurizon’s future regulatory and commercial positioning. Registration details are provided below. Participants are encouraged to submit questions in advance during the registration process or via company email to enquiries@neurizon.com.  Registration Link: https://bit.ly/NUZ-001  Date: 28 May 2026  Time: 4:00pm AEST -ENDS- This announcement has been authorised for release by Sergio Duchini, Interim Executive Chair, on behalf of the Board of Neurizon Therapeutics Limited. For further information, please contact: Neurizon Therapeutics Lidija Damjanovic Marketing & Corporate Affairs Email: lidija@neurizon.com Phone: +61 (0) 425 700 504 Australia Investor Relations Henry Jordan Six Degrees Investor Relations Email: henry.jordan@sdir.com.au Phone: +61 (0) 431 271 538 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited ABN 35 094 006 023 HEALEY ALS Platform Trial Regimen I Sample Size Expansion MAY 2026 Disclaimer This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company. Regimen I Sample Size Expansion 2 Future Matters This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. US Disclosure This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers. Agenda • Key takeaways • Recruitment momentum and execution update • HEALEY platform dynamics and rationale for expansion • Regimen I Timeline • Financial considerations • Future milestones • Q&A Regimen I Sample Size Expansion 3 Key Takeaways Increase in Neurizon’s Regimen I sample size driven by the enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period. Revised design preserves the original statistical assumptions underpinning the primary endpoint analysis and supports more robust subgroup and biomarker analysis. Larger and more informative dataset generated under the same inclusion criteria strengthens future regulatory discussions, partnering opportunities and commercial positioning. Funding requirements remain unchanged. A modest increase anticipated in total study completion costs to be offset by Philanthropic funding support from the Sean M. Healey & AMG Center for ALS. Based on current enrolment momentum, Neurizon anticipates last participant dosing in Q2 CY2027 with topline results expected in early Q3 CY2027, ahead of previous expectations. Regimen I Sample Size Expansion 4 Neurizon announced an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements. Strong Phase 2/3 ALS Trial Recruitment Momentum 64 113 193 74 Activated Sites Master Screening Dosed Participants Regimen Assignment Numbers referred to above are as of 22 May 2026. 5 Regimen I Sample Size Expansion Regimen I Sample Size Expansion Expansion of Regimen I sample from 160 to 240 participants 6 6 Original Design: • n=160 participants • 3:1 Randomisation Expanded Design: • n=240 participants • 3:1 Randomisation Expansion Driven by: • Enrolment rates exceeding original expectations • Rapid U.S. site activation and strong operational execution across the Sean M. Healey & AMG Center for ALS network • Absence of a start of a concurrent regimen during the expected recruitment window • Opportunity to generate a larger and more informative dataset under the same inclusion criteria • Potential to strengthen future regulatory, partnering, and commercial positioning • Ability to capitalise on current recruitment momentum while maintaining trial continuity and efficiency • 180 Active • 60 Placebo • 120 Active • 40 Placebo Why Expansion to 240 Matters? 7 • Maintains statistical power aligned with the original assumptions • Allows subgroups of lower prevalence to be studied • Supports additional biomarker and translational insights relevant to ALS and broader neurodegenerative diseases Stronger Dataset Improved Regulatory Credibility Improves Commercial Positioning • Stronger Evidence: Generates a larger, more informative dataset to support future regulatory interactions • Faster Execution: Accelerates time- to-topline by delivering a fully powered dataset earlier through rapid enrolment rate • Commercial Advantage: Optimises partnering and broader strategic positioning for NUZ-001 Regimen I Sample Size Expansion • Clinically meaningful benefit with ability to detect effect size maintained • Removes reliance on placebo data from concurrent regimens • Strengthens interpretability of the primary endpoint analysis • Supports future expedited regulatory pathway discussions, including Fast Track Designation, Breakthrough Designation, Priority Review and Accelerated Approval, where appropriate ‘Regimen-I’ Trial execution timelines exceed previous projections Enrollment Complete Q3-Q4 2026 First Patient Dosed 160 patients enrolled in the trial First patient screened for eligibility Last Patient Dosed Q1 2026 First Patient Screened Q2-Q3 2027 Last participant receives final dose Database Lock Q3 2027 Clinical trial database locked for analysis Topline Data Released Topline results of the trial announced Q3 2027 First participant dosed in Regimen I Platform Trial IND submitted to regulatory authorities Q4 2025 IND Amendment Submission NUZ-001 entry accepted Q4 2025 FDA Clearance Q1 2026 5 6 7 8 NOW Q3 2026 NOW Q2 2027 NOW Q2 2027 NOW EARLY Q3 2027 Expanded cohort to 240 participants Based on current enrolment rate, Neurizon anticipates accelerated trial timeline projection 8 Regimen I Sample Size Expansion Financial Considerations Accelerated time to topline readout with no change in funding requirements 9 Cost Management & Accelerated Trial Timeline Focused cost management and fast enrolment support no change to expected costs to topline read out Philanthropic Contribution from HEALEY R&D Tax Incentive Accelerating ALS research through collaboration and cost efficiency Regimen I Sample Size Expansion Additional cost being materially offset by meaningful contribution of philanthropic funds from the Sean M. Healey & AMG Center for ALS Modest increase in cost of full trial to be further offset by Australian Federal Government’s R&D Tax Incentive cash rebate Key Progress and Upcoming Milestones 10 Q3- Q4 CY 2026 ONGOING EFFORTS ü Work to broaden pipeline to other neurodegenerative diseases ü Partnership expansion opportunities with patient associations ü Targeted engagement with potential strategic partners Q2 • Preclinical updates • HEALEY enrollment updates • CEO Appointment • VIC and QLD shareholder briefing events • HEALEY tablet supply secured through completion • Liquid Formulation PK Study • EMA Protocol Advice opinion • PMDA General Consultation • HEALEY Trial enrollment complete • Participation at partnering and scientific conferences Preclinical Updates Commercial Supply Agreement with Elanco HEALEY Regimen I update Ethics Approval for Liquid Formulation PK Study EMA Scientific Advice preparation PMDA Regulatory Consultation Regimen I Sample Size Expansion Shareholder events in NSW & WA Data Strengthening MOA Understanding Upcoming Milestones in Q2 Key Progress in Q2 Upcoming Milestones Q3/Q4 Thank You Live Q&A